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1053-l 77 Motexafin Lutetium Phototherapy Decreases Vascular 
Inflammation in Rabbit Atheroma: Implications for 
Vulnerable Plaque Therapy 
Yi-Pina Surr Quan Zheng, Shanhong Ling, Patti Thieman, Wai-Fung Cheong, Daniel 
Adelman, Steven Lacy, Krishnankutty Sudhir, Pharmacyclics, Inc.. Sunnyvale, CA 
Background: Macrophage (Mac) burden is a critical determinant of plaque instability. 
Motexafin lutetium (MLu), an expanded porphyrin, decreases Mats in rabbit atheroma 
when locally administered and photoactivated. We studied the effect of MLu photother- 
apy on human Mats in vitroand the effect of systemic MLu followed by local photoactiva- 
tion (732nm) on vascular Mac burden, as well as thermal effects of balloon Illumination in 
viva Methods: In vitro Human monocyies (THP-1) were cultured with MLu (10 pg/ml), 
then photoactivated (2 J/cm?; drug uptake (histofluorescence), growth and differentia- 
tion (cell count) were assessed. In viva: After 14 wks on 2% chol, 48 rabbits were ran- 
domized to 7 groups: (1) Control (5% mannitol); (2) MLu (10 mg/kg); (3) Light (100 J/cm’ 
in balloon, 300 J/cm’ with bare fiber); and MLu + light, 10, 30. 100 and 300 J/cm’ as 
groups 4-7. Light was delivered to upper thoracic aolta via a balloon and lower thorawl 
abdominal aorta by a bare fiber for 900 secslsite, 24h after i.v. MLu. AHer 3 more wks, 
aortas were examined for plaque (I/M ratios) and Mats (RAM-1 1 stain). Six more animals 
underwent balloon illumination (30-300 J/cm’) with adventitial temperatures of vessels 
continuously recorded by an infrared camera. Results In vitro, MLu was taken up by 
Mats 30 min post incubation and retained over 24h. MLu reduced monocyte differentia- 
tion to Mats (43.6% of control, p<O.Ol). MLu phototherapy (24h) induced apoptotic death 
in Mats (44.8+3.2% vs. control 9.&1.0%, pcO.01). In viva, MLu phototherapy at lower 
light levels reduced vascular Mac burden (% total intima area) from 28.1+4.1 (control) to 
14.2i6.4 at 10 J/cm’ and 16.4k5.2 at 30 J/cm’ in balloon (p<O.O5), and from 8.9+1.8 
(control) to 4.4i1.5 at 30 J/cm’ and 4.5+2.0 at 100 J/cm’ with bare fiber (p<O.O5), but did 
not change plaque burden. Adventitial temperature increased up to 15’C at 300 J/cm’ 
and 3’C at 100 J/cm’, with no change at 30 J/c&. Conclusions: MLu phototherapy 
decreases Mac burden at lower light fluence, in the absence of regression, possibly by 
reduction of monocyie diflerentiation and induction of Mac apoptosis. Thermal effects at 
high light fluence may reduce efficacy. MLu phototherapy may be useful in plaque stabili- 
zation. 
1053-l 97 Long-Term Effects of Octreotide Therapy: A 
Somatostatin Analog, on In-Stent Flestenosis 
Hurkan Kursaklioglu, Atila Ivisoy, Sedat Kose, Turgay Celik, Cem Barcin, Basri Amasyali, 
Nadir Earindik, Ertan Demirtas. Gulhane Military Medical Academy (GATA), Ankara, 
Turkey 
Background: Although somatostatin analogs have been shown to reduce neointimal 
reaction in animal models but to have no definitely good result in human aHer balloon 
angioplasty, their roles in reducing in-stent restenosis in human have not been evalu- 
ated. Neointimal hyperplasia shown to be decreased by the octreotide therapy is 
accepted as the predominate mechanism of in-stent restenosis as well as neointimal 
hyperplasia is only one of the major responsible mechanisms of restenosis aHer angio- 
plasty. The purpose of this study was to assess the long-term effects of octreotide on the 
in-stent restenosis at six-month follow-up coronary angiography. 
Methods: In a placebo-controlled, randomized study, of the 176 patients, the finally eval- 
uable 148 patients with significant coronary disease (stenosis > 70%) amenable to stent- 
ing were randomly allocated to octreotide therapy with a dose of 300 mg or placebo 
subcutaneously every eight hours for three weeks. The primary endpoint of the study 
was the restenosis rate after stenting at 6-month follow-up. Restenosis was defined as 
recurrent lumen diameter stenosis >50% at follow-up angiography. Stenting was consid- 
ered successful if the residual diameter stenosis was less than 10%. 
Results: There was no sianiflcant difference between octreotide and placebo aroups in _. 
the pre (85.8% * %6.5 and 85% * %9.4, paO.05) and poststenting mean percent diame- 
ter stenoses (7.6% * 2.1% vs. 7.4% * 2.2%. 0~0.05) resoectivelv. The mean oercent 
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diameter stenoses at the B-month control angiographies of octreotide and placebo 
groups were significantly different from each other. (35% * 19.2% vs. 18.8% * 14.2 
respectively, p=O.OOl). At the six-month, the restenosis rate was 12% (9 of 76 patients) 
in the octreotide group and 26% (19 of 72 patients) in the control group. The difference 
between the two groups was significant (pcO.05). We found an OR of 0.37 with a 95% Cl 
of 0.14-0.96 (p=O.O36), when octreotide was given to our patients undergoing to stenting. 
Conclusion: Due to our findings, octreotide caused a significant reduction on in-stent res- 
tenosis. We proposed that these results could be related to the inhibiting effect of oct- 
reotide on neointimal hyperplasia after stenting. 
1053-l 98 lntracoronary Calcium Channel-Blocker Is Associated 
With Earlier Release of Cardiac Enzymes After Coronary 
Intervention 
Ian C. Gilchrist. Sr, Mark Matthews, Joseph A. Gascho, Susan J. Kunselman, 
Pennsylvania State University, Hershey, PA 
Background: Nitroglyercin (NTG) and calcium channel blockers (CCB) dilate the epicar- 
dial coronary arteries while CCB may further vasodilate the microcirculation. If microcir- 
culation impairment plays a role in peri-procedural myocardial infarctions, we 
hypothesized that the use of an intracoronary (IC) calcium channel blocker during PCI 
would result in alterations in myocardial enzyme release after PCI compared with NTG. 
Methods: 816 sequential patients, undergoing PCI without evolving infarction, were 
abstracted retrosoectivelv for demoaraohics. oeri-orocedural medications and details ~ _. 
that might impact on outcome of CPK release. CPK enzymes were routinely ordered at 6, 
12. and 18 hours after PCI. IC-CCB or NTG use was soecificallv noted and reflected _ 
operators standard choice. Post-procedural CPK levels were analyzed using both a 
repeated measures (ANOVA) and a random coefficient model using a quadratic function. 
Results: CCB (n=401) and the NTG (n=415) had similar background characteristics and 
net elevations of CPK. IC-CCB group had an earlier rise in CPK (p=.OOO2 by 8 hrs) and 
an earlier peak (16.3 hrs vs 26.1 hrs) compared with the IC-NTG group. 
Conclusions: Routine IC-CCB use is associated with an earlier rise of CPK enzymes 
after PCI. This supports the role of CCB as vasodilators of the microcirculation and sug- 
gests further avenues for research In enhancing blood flow at the tissue level of the myo- 
cardium during PCI. 
1053-l 99 Effect of Simvastatin on the Inflammatory Response to 
Coronary Angioplasty 
Christopher J. Hammett, Ralph A. Stewart, John K. French, Cheuk-Kit Wang, Mark W. 
Webster, John A. Ormiston, Wanzhen Gao. Harvey D. White, Green Lane Hospital, 
Auckland, New Zealand 
Background: Previous studies have reported treatment with the HMG-CoA reductase 
inhibitor simvastatin reduces serum C-reactive protein (CRP) levels, suggesting an anti- 
inflammatory effect that appears to be fully established within 4 weeks of commencing 
therapy. Coronary angloplasty is associated with an acute increase rn serum inflamma- 
tory markers which may predict early complications. The effect of simvastatin on this 
inflammatory marker rise is unknown. The aim of this study was to determine whether 
pre-treatment with slmvastatin reduces the inflammatory response to coronary angio- 
plasty. 
Methods: We studied 92 patients (mean age 60*10 years) randomised to simvastatin 
40mgld (n=52) or placebo (n=40) a median of 1.9 months (IQR 0.9 to 3.6 months) before 
elective coronary angioplasty. All patients were taking aspirin 150mgIday unless there 
was a specific contraindication (aspirin use 92% for simvastatin group, 95% for placebo 
group, p=ns). CRP was measured by high sensitivity immunoassay on serum samples 
taken immediately prior to and 48 hours after angioplasty. 
Results: The CRP (median[lQR]) immediately prior to angioplasty was 1.3mgIl (0.71- 
2.43) for the placebo group, versus 1.46mgA (0.67-2.14) for the simvastatin group, 
p=O.79. CRP increased post-PC1 for both groups (p<O.OOi for both simvastatin and pla- 
cebo). Simvastatin did not alter this inflammatory response; the increase in CRP (pre- 
angioplasty to 48 hours post-angioplasty) for patients randomised to simvastatin was 
4.68mgIl (IQR 2.9 to 10.3) compared to 5.1fJmg/l (IQR 2.2-9.3) for placebo, (p=O.96). 
Exclusion of patients on simvastatin for less than 4 weeks prior to angioplasty did not 
alter this result. 
Conclusion: There is an increase in CRP measured 48 hours after angioplasty, confirm- 
ing an inflammatory response. Simvastatin did not significantly influence this inflamma- 
tory response. 
1053-200 Neither Periprocedural Pregnancy-Associated Plasma 
Protein A nor C-Reactive Protein Levels Predict 
Restenosis 
Christopher J. Hammett, John K. French. Michael Christiansen, Claus Oxvig. Michael T. 
Overgaard. Bruce J. Webber, Ralph A. Stewart, Cheuk-Kit Wang, Mark W. Webster, 
John A. Ormiston, Wanzhen Gao, Harvey D. White, Green Lane Hospital, Auckland, 
New Zealand, Statens Serum Institut, Copenhagen, Denmark 
Background: Matrix metalloproteinases including Pregnancy-Associated Plasma Pro- 
tein A (PAPP-A) are abundantly expressed at sites of atherosclerotic plaque rupture, are 
predictive of acute coronary syndromes when circulating levels are elevated, and may 
play an important role in the development of restenosis following percutaneous coronary 
intervention (PCI). C-reactive protein (CRP) levels increase following PCI. peaking at 48 
to 72 hours, but the effect of this inflammatory response on restenosis IS unclear. The 
aim of this study was to determine whether peri-procedural levels of PAPP-A and/or CRP 
predict restenosis. 
Methods: We studied 136 patients with stable angina who underwent elective PCI with 
stored peri-procedural blood samples and corresponding pre-. post-, and six month coro- 
nary angiograms; age (mean&D) 59+10 yrs, 83% male. slant insertion rate 14%. CRP 
and PAPP-A were measured by high sensitivity immunoassay on EDTA-plasma samples 
which had been taken immediately prior to, and 48 hours post, PCI. All results are 
expressed as median (IQR). Restenosis (diameter stenosis ~50%) six months after PCI 
was determined by quantitative coronary angiographic @CA) analysis. In multi vessel 
PCI (39% of patients), analysis was done on a “per patient” basis by averaging the per- 
cent diameter stenosis of all lesions. 
Results: PCI was associated with a significant rise in both CRP and PAPP-A levels; 
CRP prior to PCI 1.2mgA (0.7-2.2), post-PC1 6.6mg/l (4.0.13.2), pcO.0001, PAPP-A prior 
to PCI 4.lmlUll (3.3&l), post-PC1 b.BmlU/I (4.3-7.2), p<O.OOOl. The median stenosis at 
six months was 46% (IQR 34.63%) and the binary restenosis rate was 42%. There were 
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no associations between either pre-PCI or post-PC1 levels of CRP or PAPP-A and steno- 
sis at six months (~~-0.15 for all comparisons). 
Conclusion: PCI leads to a significant post-procedural increase in both CRP and PAPP- 
A levels at 48 hours, but this systemic response was not associated with restenosis rates 
at six months. 
t053-201 Fasting Plasma Insulin Is an Independent Predictor of 
Cardiac Events at One Year After Percutaneous 
Coronary Revascularization 
Karine S&i&e, Jean Marc Lablanche, Grbgory Perrard, Jean-Marc Aubert, SBbastien 
Caudemont, Pascal Pigny, Franpois Cuilleret, Sophie Susen, Christophe Bauters. Jean 
Charles Fruchart, Eric Van Belle, Hospital Cardiologique, Lille, France, lnstitut Pasteur, 
Lille, France 
Diabetes is one of the major risk factor for cardiac events following percutaneous coro- 
nary revascularisation (PCR). However, the role of hyperinsulinism is unclear in this clin- 
ical context. Our objective was to determine the predictive value of fasting plasma insulin 
measured immediately before PCR on subsequent cardiac events. Patients who under- 
went primary or rescue PCR for an acute Ml were excluded. A total of 261 consecutive 
patients, including 82 diabetics (31%), had blood sample measurement of fasting insulin, 
glycemia, and hs-CRP immediately before PCR. The primaly endpoint was a composite 
of death, non-fatal Ml and rehospitalisation for unstable angina. The actuarial rate of 
events was 9.6% at 1 year. 
Multivariate analysis was performed including risk factors such as age, gender, diabetes, 
smoking status, family history of CAD, hypertension, hyperlypidemia, unstable angina, 
left ventricular ejection fraction, extent of CAD, hs-CRP, glycemia and fasting insulin. 
Four independent predictors of events were found in this population: hs-CRP (p=O.OOOl), 
diabetes (p=O.O07), fasting insulin (p=O.Ol) and LVEF (~~0.05). The risk associated with 
high insulin levels (insulin>1 lmUI/L) was more apparent in non-diabetic than in diabetic 
patients (see Table). Conclusion: Fasting insulin measured at baseline is an independent 
predictor of cardiac events at 1 year after PCR. Our results suggest that measurement of 
fasting insulin before PCR may help to identify of group of patients at high risk. 
” events (%) p 
non-diabetics, insulin<1 1 mUIlL 155 5.8% 0.01 
non-diabetics, insulm>ll mu/L 24 18.2% 
Diabetics, insulin<11 mUI/L 57 15.8% 0.10 
Diabetics, insulin>llmU/L -25 26.1% 
1053-202 Subacute Stent Thrombosis After Sirolimus-Eluting 
Stent Implantation in Daily Practice: Results From the 
mpamycin Eluting-Stent Evaluated at Rotterdam 
Hospital (Research) Registry 
Evelyn Reaar, Pedro A. Lemos, Chi-Hang Lee, Kengo Tanabe. Francesco Saia. 
Muzaffer Degertekin, Chourmourios A. Arampatzis, Pim de Feyter, Willem J. van der 
Giessen, George Sianos, Pieter Smits, Ron T. van Domburg, Patrick W. Serruys, 
Erasmus University Medical Center, Rotterdam, The Netherlands 
Background: The incidence of subacute stent thrombosis (SAT) after sirolimus-eluting 
stent (SES) implantation for complex lesions is currently not known. We analyzed the 
occurrence of SAT in a large series of consecutive patients treated with this new tech- 
nique. 
Methods: Since 16” April 2002, SES implantation has been adopted as the default strat- 
egy for all patients treated with percutaneous intervention at our institution, as part of the 
RESEARCH registry. Patients were included irrespecbve of clinical presentation and 
lesion morphology. SAT was defined as any thrombotic in-stent occlusion occurring after 
the index procedure. 
Results: By tih September 2002, a total of 479 consecutive procedures were performed 
utilizina at least one SES. Mean aoe was 61*11 years. 71% were men. Overall. 229 
(48%) patients presented wth an acute coronary syndrome and 92 (19%) were diabetic. 
Platelet qlvcomotein inhibitors were used in 119 (25%) orocedures. From a total of 1004 
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SES utilized. 708 (71%) were implanted in type 62/C lesions and 100 (10%) had small 
nominal diameter (2.25 mm). Reference diameter was 2.69 * 0.57 mm. Post-procedure 
MLD and diameter stenosis were 2.28kO.54 mm and 14.7+13.2 mm, respectively. To 
date (mean follow-up period 63+38 days; median 60 days), SAT occurred in 2 patients 
(0.4%), one re-admitted with acute myocardial infarction (within 6 hours after the initial 
procedure) and one with rest pain unstable angina (after 11 days). Both were success- 
fully treated with percutaneous re-intervention. 
Conclusions: Utilization of sirolimus-eluting stent implantation as the strategy of choice 
in the “real world’ of interventional cardiology IS associated with a very low incidence of 
subacute stent thrombosis. 
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1075MP-163 Current Status of Percutaneous Coronary Intervention: 
Results From a Large International Trial 
9:00 a.m. 
Heidar Ariomand. James T. WilIerson, David R. Holmes, Prem Kittusamy, Satish 
Surabhi. Bassam Roukoz, Andrey Espinoza, Daniel McCormick, Zoltan G. Turi, Sheldon 
Goldberg, Drexel University College of Medicine, Philadelphia, PA, Mayo Clinic, 
Rochester, MN 
Background: Recently, there has been a significant evolution in the specific techniques 
of percutaneous coronary intervention (PCI) and adjunctive pharmacologic therapies. To 
assess the impact of these changes, we evaluated the outcomes of contemporary PCI 
performed in a large international trial. 
Method: We analyzed clinical and anQiOgraphiC characteristics, techniques of PCI, and 
30-day and l-year outcomes of 7,787 patients with de nova lesions who underwent suc- 
cessful PCI between April 1999 and July 2000 as a part of the Prevention of Restenosis 
with Tranilast and its Outcomes (PRESTO) trial. 
Results: Mean patient age was 60 yrs and 77% were male. Baseline clinical features 
were: diabetes: 22%, hypercholesterolemia: 47%, hypertension: 57%, prior Ml: 31%, and 
prior CABG: 9%. Angiographic lesion characteristics included: mean diameter stenosis: 
87.5%, mean lesion length: 13.3 mm, calcified lesions: 18%, bifurcation lesions: 10%. 
total occlusions: lo%, ostial lesions: 6%, and lesions with definite or possible thrombus: 
34%. Overall, 81.7% of patients had single-vessel PCI, 16.5% had two-vessel PCI, and 
1.7% had three-vessel PCI. Device use was: stent: 90.3%. plain balloon angioplasty: 
8.8%. rotablator: 2.5%, and laser, DCA, TEC, and angiojet, each < 1%. All pabents 
received aspirin; patients undergoing stent placement were also treated with a thienopy- 
ridine. GP Ilb/llla inhibitors were used in 35% of patients. Cardiac events at 30 days 
Included: Ml: 0.28%. death: 0.19%, CABG: 0.05%. TVR: 0.50% and any event: 1.17%. At 
9 months, event rates were: Ml: 0.77%, death: 0.82%, CABG: 2.7%. TVR: 10.8%. and 
any event: 12.8%. 
Conclusions: In this large multicenter international trial, bare stem usage was higher 
than in all prior reports, and was associated with a very low 30-day and g-month cardiac 
events. These data can serve as a benchmark against which future trials of coated stents 
can bs compared. 
9:12 a.m. 
1075MP-164 The Role of Acetylcysteine in Preventing Contrast- 
Induced Nephropathy Following Cardiac 
Catheterization in Patients With Acute and Chronic 
Renal Failure 
Nikita K. Gill Elizabeth A. Piccione, Diane Vido, Barbara A. Clark, Richard P. Shannon, 
Allegheny General Hospital, Pittsburgh. PA 
Background: Previous studies have shown a benefit with acetlycysteine (ACET) in pre- 
venting contrast-induced nephropathy. but studied only patients with chronic, stable renal 
failure undergoing elective procedures. We hypothesized that those same benefits may 
not hold true for patients in a clinical sening with acute renal failure or in the absence of 
hydration as might ocwr in patients requiring urgent cardiac catheterization. 
Methods: We evaluated the records of 146 consecutive patients with baseline renal 
insufficiency (Cr 21.2 mg/dl) that underwent cardiac catheterization or peripheral angiog- 
raphy (C&h). Patients who received hydration and ACET (600 mg po BID for two days 
peri-procedure) were included in the ACET group. Patients who simply were hydrated or 
received no pre-treatment sewed as controls (Con). Patients were excluded if they had 
an intraaortic balloon pump. bypass within 48 hours, hypotension or inadequate labora- 
tory follow-up. We compared the 48.hour change in serum creatinine (Creat) between 
groups and further analyzed the eflect of hydration on the observed outcomes in both 
groups. 
Results: The two groups were similar in age (Con: 7121; ACET: 70tl yrs), co-morbidi- 
ties (DM, CHF, HTN), amount of contrast used (Con: 151+14; ACET: 146214 ml) and 
cases of chronic versus acute renal failure. Baseline Great (Con: 1.99iO.l I; ACET: 
1.85+0.07 mgldl) was not different. Post procedure, the Great increased significantly 
(w.04) in both groups, but less so in the ACET group (Con: 0.35+0.08: ACET: 
0.14+0.04 mgidl, pa.02). When peri-procedure hydration was considered, the increase 
in Creat for the fully hydrated Con group was only O.li’iO.10 mgldl and not different from 
ACET (0.14iO.04 mQ/dl). In Con patients with inadequate peri-procedure hydration, the 
increase in Great was significantly greater (0.54r0.12 mg/dl) compared to ACET 
(0.17r0.10 mg/dl, pg.001). 
Conclusions: In unselected patients with acute and chronic renal insufficiency undergo- 
ing non-elective Cath, there was no benefit to ACET administration beyond hydration 
akYle. 
